Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase II clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. The company was founded in 2009 and is based in Jerusalem, Israel. Show More...
-
Website http://www.enterabio.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 1.85 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.36 -0.45 -0.94 -1.31 -0.89 -0.79 Dividends USD Payout Ratio % * Shares Mil 12.0 12.0 12.0 8.0 12.0 14.0 Book Value Per Share * USD -2.92 0.23 0.55 Free Cash Flow Per Share * USD -0.7 -0.69 Return on Assets % -155.88 -26.55 -114.47 -77.42 -71.86 -80.62 Financial Leverage (Average) 1.32 1.4 1.52 Return on Equity % -97.98 -121.26 Return on Invested Capital % -95.39 -116.92 Interest Coverage Current Ratio 2.36 0.52 6.15 6.97 3.41 2.84 Quick Ratio 1.5 0.39 5.81 6.85 3.37 2.68 Debt/Equity 0.010 0.010